



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

产品名称: **YS-49**
产品别名: **YS-49**

生物活性:					
Description	YS-49 is a PI3K/Akt (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits angiotensin II (Ang II)-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1. YS-49 is also an isoquinoline compound alkaloid, has a strong positive inotropic action through activation of cardiac β -adrenoceptors[1][2][3].				
In Vitro	YS-49 (1-100 μ M; 18 hours; RAVSMC and RAW 264.7 cells) concentration-dependently inhibits the accumulation of nitrite in both RAVSMC and RAW 264.7 exposed to lipopolysaccharide (LPS) plus INF- γ with IC50 values of 22 μ M and 30 μ M, respectively[2].				
	YS-49 (10-100 μ M; 18 hours; RAVSMC and RAW 264.7 cells) suppresses iNOS gene expression induced by LPS and/or cytokines in RAVSMC and RAW 264.7 cells at the transcriptional level[2].				
	Cell Viability Assay[2]				
	Cell Line:	RAVSMC and RAW 264.7 cells			
	Concentration:	10 μ M, 30 μ M and 100 μ M (RAVSMC cells); 1 μ M, 10 μ M and 100 μ M (RAW 264.7 cells)			
	Incubation Time:	18 hours			
	Result:	Inhibited the accumulation of nitrite in both RAVSMC and RAW 264.7 exposed to LPS+INF- γ , with IC ₅₀ values of 22 and 30 μ M, respectively.			
	Western Blot Analysis[2]				
	Cell Line:	RAVSMC and RAW 264.7 cells			
	Concentration:	10 μ M, 30 μ M and 100 μ M			
	Incubation Time:	18 hours			
Result:	Concentration-dependently inhibited the expression of iNOS protein induced by LPS plus IFN- γ .				
In Vivo	YS-49 (5 mg/kg; intraperitoneal injection; 8 hours; male Sprague Dawley rats) treatment significantly reduces serum NOx levels in LPS-treated rats, the NOx levels reduce from 86 μ M to 34 μ M ^[2] .				
	Animal Model:	Male Sprague Dawley rats (250-300 g)[2]			
	Dosage:	5 mg/kg			
	Administration:	Intraperitoneal injection; 8 hours			
	Result:	Serum NOx levels were significantly reduced.			
In Vitro:					
DMSO : $\geq$ 100 mg/mL (258.88 mM)					
* " $\geq$ " means soluble, but saturation unknown.					
Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	2.5888 mL	12.9440 mL	25.8880 mL
		5 mM	0.5178 mL	2.5888 mL	5.1776 mL
		10 mM	0.2589 mL	1.2944 mL	2.5888 mL
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反					



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

Solvent&Solubility	复冻融造成的产品失效。 储备液的保存方式和期限 -80℃, 6 months; -20℃, 1 month。 -80℃ 储存时, 请在 6 个月内使用, -20℃ 储存时, 请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂: ——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶 1.请依序添加每种溶剂: 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution 此方案可获得 ≥ 2.5 mg/mL (6.47 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中, 混合均匀; 向上述体系中加入 50 μL Tween-80, 混合均匀; 然后继续加入 450 μL 生理盐水定容至 1 mL。 2.请依序添加每种溶剂: 10% DMSO→ 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution 此方案可获得 ≥ 2.5 mg/mL (6.47 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中, 混合均匀。 3.请依序添加每种溶剂: 10% DMSO →90% corn oil Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution 此方案可获得 ≥ 2.5 mg/mL (6.47 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中, 混合均匀。
References	[1]. Sun JJ, Kim HJ, Seo HG, et al. YS49, 1-(alpha-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, regulates angiotensin II-stimulated ROS production, JNK phosphorylation and vascular smooth muscle cell proliferation via the induction of heme oxygenase-1. Life Sci. 2008;82(11-12):600-7. [2]. Kang YJ, et al. Prevention of the expression of inducible nitric oxide synthase by a novel positive inotropic agent, YS 49, in rat vascular smooth muscle and RAW 264.7 macrophages. Br J Pharmacol. 1999 Sep;128(2):357-64. [3]. Hsu YH, et al. RhoA-mediated inhibition of vascular endothelial cell mobility: positive feedback through reduced cytosolic p21 and p27. J Cell Physiol. 2014 Oct;229(10):1455-65.